Table 1 The diagnostic efficacy evaluation of serum fucosylated exosomal miR-47323-3p for NSCLC
Serum fucosylated exosomal miR-47323-3p | AUC-ROC (95% CI) | Sensitivity% (95% CI) | Specificity% (95% CI) | Positive predictive value% | Negative predictive value% |
|---|---|---|---|---|---|
HC + BPN vs. NSCLC | 0.823 (0.758–0.889) | 67.71 (57.83–76.22) | 90.32 (80.45- 95.49) | 91.55 | 64.37 |
HC vs. NSCLC | 0.886 (0.798–0.969) | 90.63 (83.13–94.99) | 84.38 (68.25–93.14) |  |  |
BPN vs. NSCLC | 0.759 (0.679–0.840) | 67.71 (57.83–76.22) | 90.00 (74.38–96.54) |  |  |
Tis vs. Stage I/II | 0.823 (0.715–0.930) | 67.66 (0.84 -80.87) | 96.77 (83.81–99.83) |  |  |
Tis vs. Stage III/IV | 0.946 (0.894–0.998) | 83.87 (67.37–92.91) | 93.55 (79.28–98.85) |  |  |
Stage I/II vs. Stage III/IV | 0.808 (0.694–0.923) | 67.74 (50.14–81.43) | 97.06 (85.08- 99.85) |  |  |